Education
About Us
Working with TipRanks
Follow Us
MindWalk Holdings (DE:TQB0)
FRANKFURT:TQB0
TQB0 Stock Chart & Stats
€1.11
-€0.01(-2.24%)
At close: 4:00 PM EST
€1.11
-€0.01(-2.24%)
Day’s Range― - ―
52-Week Range€0.20 - €2.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)487.00
Market Cap
$57.58M
Enterprise Value€70.75M
Total Cash (Recent Filing)$16.51M
Total Debt (Recent Filing)$3.63M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Mar 18, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding46,691,280
10 Day Avg. Volume400
30 Day Avg. Volume487
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.85
Price to Sales (P/S)0.83
P/FCF Ratio-2.80
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue3.45
Enterprise Value/Gross Profit6.30
Enterprise Value/Ebitda-2.27
Forecast
1Y Price Target
$4.24Price Target Upside282.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development And Partnership StrategyManagement's plan to complete preclinical work, initiate a Phase 1 clinical study, and seek a development and commercial partner could accelerate clinical validation and broaden market access for lead candidates.
Non-dilutive Financing And Asset-level FundingIntention to create segregated portfolios in a Cayman Islands structure allows investors to fund individual machine learning–discovered candidates directly, potentially providing non-dilutive capital to advance programs.
Universal Vaccine PotentialDiscovery of a conserved functional constraint across influenza strains could enable development of a universal influenza vaccine, offering a disruptive commercial opportunity if clinical proof of concept is achieved.
Bears Say
Commercial And Execution RiskAnalyst notes commercial challenges and execution failures could hinder market penetration and delay revenue realization from new vaccine programs.
Competitive PressureAnalyst highlights competition from established vaccine developers and novel entrants that could erode market share and compress pricing for new influenza offerings.
Legal And Intellectual Property RiskAnalyst warns that potential legal disputes and intellectual property conflicts could impose costs, restrict development activities, or limit licensing opportunities.
MindWalk Holdings News
TQB0 FAQ
What was MindWalk Holdings’s price range in the past 12 months?
MindWalk Holdings lowest stock price was €0.20 and its highest was €2.80 in the past 12 months.
What is MindWalk Holdings’s market cap?
MindWalk Holdings’s market cap is $57.58M.
When is MindWalk Holdings’s upcoming earnings report date?
MindWalk Holdings’s upcoming earnings report date is Mar 18, 2026 which is in 23 days.
How were MindWalk Holdings’s earnings last quarter?
MindWalk Holdings released its earnings results on Dec 15, 2025. The company reported -€0.043 earnings per share for the quarter, missing the consensus estimate of -€0.031 by -€0.012.
Is MindWalk Holdings overvalued?
According to Wall Street analysts MindWalk Holdings’s price is currently Undervalued.
Does MindWalk Holdings pay dividends?
MindWalk Holdings does not currently pay dividends.
What is MindWalk Holdings’s EPS estimate?
MindWalk Holdings’s EPS estimate is -0.03.
How many shares outstanding does MindWalk Holdings have?
MindWalk Holdings has 46,691,280 shares outstanding.
What happened to MindWalk Holdings’s price movement after its last earnings report?
MindWalk Holdings reported an EPS of -€0.043 in its last earnings report, missing expectations of -€0.031. Following the earnings report the stock price went down -3.289%.
Which hedge fund is a major shareholder of MindWalk Holdings?
Currently, no hedge funds are holding shares in DE:TQB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MindWalk Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.24 (282.09% Upside)
$4.24 (282.09% Upside)
Blogger Sentiment
Bullish
DE:TQB0 Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
225.06%
12-Months-Change
Fundamentals
Return on Equity
-121.76%
Trailing 12-Months
Asset Growth
-56.69%
Trailing 12-Months
Company Description
MindWalk Holdings
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
TQB0 Company Deck
TQB0 Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a generally positive outlook for MindWalk, with significant revenue growth, improved gross profit margins, and strategic initiatives like the divestiture of noncore operations and the launch of BioNative AI and HYFT technology. While there are challenges such as operating and net losses, the company's strong cash position and strategic focus on AI-driven R&D suggest a promising future.View all DE:TQB0 earnings summariesTQB0 Stock 12 Month Forecast
Average Price Target
€4.24
▲(282.09% Upside)
Technical Analysis
XBiotech
―
Relmada Therapeutics
―
PMV Pharmaceuticals
―
Werewolf Therapeutics
―
Estrella Immunopharma
―
Options Prices
Currently, No data available
---